The 4⃣th NEJM from #ASCO22 DESTINY Breast04 Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced #BreastCancer ✅trastuzumab deruxtecan resulted in significantly longer PFS &OS🆚Chemo🧪 ✅OS 23.9 mo🆚17.5 mo ✅PFS 10.1🆚5.4 mo OncoAlert 🚨 nejm.org/doi/full/10.10…

Congrats to all of team Mayo - from the facility engineers to the nurses to the scientists, physician investigators, to the schedulers and rooming teams and everyone in between who each strive everyday to put patients first. newsnetwork.mayoclinic.org/discussion/may…

Congrats to all for a great match week! We are very excited to welcome our incoming class of Hematology Oncology fellows at the Mayo Clinic Arizona Mayo Clinic Comprehensive Cancer Center

Happy to share our now published #DB03 update! @oncoalert #SABCS22 Trastuzumab deruxtecan versus TDM1 in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial - ScienceDirect sciencedirect.com/science/articl…

yes! this is the why

couldn’t agree more

biomarkers require either better treatment to change the outcome (salvage the situation by using the information) but also valuable to determine futility which is meaningful when it’s humans you treat

Happy to share our new Science Translational Medicine paper. It turns out simply measuring plasma DNA fragments that break at unexpected positions across the genome holds promise as a cancer biomarker for detection and monitoring science.org/doi/10.1126/sc…

We need more development and validation before this is ready for the clinic but I am hopeful this approach can become accessible and cost-effective for cancer detection and monitoring in the US and around the world.

Much thanks to Karan, Bradon and Michelle who led this work, everyone in the lab @UW_CHGPM UW-Madison Department of Surgery UW–Madison, collaborators including @TGen Mayo Clinic Yale Cancer Center, patients who participated in these studies, and funding from National Cancer Institute that made this work possible.

such a privilege to sit Mayo Clinic Faculty Development 2023: Empowering Medical Educators and listen to this incredible speaker Margaret Johnson MD - all learners are lucky to have you.

It is the only way

#diversitymatters glad to see this more and more but we need to put this to action

Important data on exercise and improved QOL in our MBC pts. #sabcs23

If anyone missed it please watch virtually Dr. E Mittendorf talk on career paths. #SABCS23

It’s Thank a resident/ fellow day today!! We have the most amazing Hematology and Oncology fellows at Mayo Arizona! Either today or in the days ahead - take a moment to tell a doc in training Thank you- for the hard work and dedication they spend learning how to be great docs

Link is now open for those interested! #bcsm #supponc

🖤 Heartbroken that swaggsheila's incredible voice is gone. Her joy, strength, and humor uplifted so many. Her guiding light shines on all of us to continue working to improve cancer care. The status quo isn't good enough. We need more. We need better. #stageIVneedsmore

Navigating the Road to Success: Early Funding for Research and Beyond— Larissa Korde, Sara Tolaney, and Minetta Liu addressed this topic in a Career Development session moderated by Brenda Ernst this afternoon at #SABCS24. Sara Tolaney Brenda Ernst, MD